Aeterna Zentaris Presented Poster on Oral Prostate Cancer Vaccine, AEZS-120, at International Urology Conference in Japan

 Aeterna Zentaris Presented Poster on Oral Prostate Cancer Vaccine, AEZS-120,
                 at International Urology Conference in Japan

PR Newswire

QUEBEC CITY, Oct. 2, 2012

Filing of Clinical Trial Application (CTA) in Prostate Cancer Expected in Q4

QUEBEC CITY, Oct. 2, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS)
(TSX:AEZ) (the "Company") today announced that preclinical data on its oral
prostate cancer vaccine candidate, AEZS-120, were presented over the weekend
at the 32^nd Congress of the Société Internationale d'Urologie, which is being
held in Fukuoka, Japan. The presentation underlined the feasibility of an oral
therapeutic vaccination approach against prostate cancer. Furthermore, safety
pharmacology and toxicology data suggest that the profile of AEZS-120 is
similar to the approved carrier strain and, therefore, pave the way for Phase
1 clinical testing.

Juergen Engel, PhD, President and CEO at Aeterna Zentaris, commented, "Now
that we have completed the preclinical development program for AEZS-120, we
look forward to filing a Clinical Trial Application in Europe during this
quarter, in order to initiate a Phase 1 clinical trial in prostate cancer with
this novel oral anticancer vaccine."

Summary and Conclusions

The production, release, pharmacology, safety and toxicology program was
conducted in agreement with the regulatory authorities and successfully

  *The proof of concept has been shown in a tumor-challenge mouse model using
    the anticipated clinical application schedule;
  *Biosafety and biodistribution studies did not reveal a different safety
    profile compared to the carrier strain;
  *Pharmacological and toxicological studies did not reveal differences to
    the approved carrier strain;
  *In all, the non-clinical studies suggest that the safety and toxicological
    profile of AEZ-120 is similar to the approved carrier strain S. typhi
    Ty21a, which has already been safely applied in more than 250 million
  *GMP material for clinical use has been produced and released; and CTA
    filing for Phase 1 clinical study is planned in 4Q 2012.

The poster titled, "Preclinical Proof of Concept and Characterization of
AEZS-120, a Therapeutic Oral Prostate Cancer Vaccine Candidate Based on Live
Recombinant Attenuated Salmonella", J. Fensterle, B. Bergmann, P. Schmidt, M.
Teifel, J. Engel, T. Rudel, W. Goebel, and U. Rapp, can be viewed by clicking
on the following link.

About AEZS-120

AEZS-120 is a live recombinant oral tumor vaccine candidate based on
Salmonella typhi Ty21a as a carrier strain. Salmonella typhi Ty21a is an
approved oral typhoid vaccine which has been safely applied in more than 250
million doses. The principle of AEZS-120 is based on the recombinant
expression of prostate specific antigen fused to the B subunit of cholera
toxin and a secretion signal in the presence of the Escherichia coli type I
hemolysin secretion system. The proprietary system allows the secretion of the
antigen, together with an immunological adjuvant which has been demonstrated
to be required for optimal induction of CD8 T-cell responses by recombinant
Salmonella based bacterial vaccines. The proof-of-concept was demonstrated for
the mouse homologue of AEZS-120 in a mouse tumor-challenge model. In general,
by varying the antigen and/or the carrier, this proprietary platform
technology should be suitable for virtually any therapeutic or prophylactic
vaccine indication with a favorable cost of goods expectation in large scale.

About Aeterna Zentaris

Aeterna Zentaris is an oncology and endocrinology drug development company
currently investigating treatments for various unmet medical needs. The
Company's pipeline encompasses compounds at all stages of development, from
drug discovery through to marketed products. For more information please visit

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the
safe harbour provisions of the U.S. Securities Litigation Reform Act of 1995.
Forward-looking statements involve known and unknown risks and uncertainties
that could cause the Company's actual results to differ materially from those
in the forward-looking statements. Such risks and uncertainties include, among
others, the availability of funds and resources to pursue R&D projects, the
successful and timely completion of clinical studies, the risk that safety and
efficacy data from any of our Phase 3 trials may not coincide with the data
analyses from previously reported Phase 1 and/or Phase 2 clinical trials, the
ability of the Company to take advantage of business opportunities in the
pharmaceutical industry, uncertainties related to the regulatory process and
general changes in economic conditions. Investors should consult the Company's
quarterly and annual filings with the Canadian and U.S. securities commissions
for additional information on risks and uncertainties relating to
forward-looking statements. Investors are cautioned not to rely on these
forward-looking statements. The Company does not undertake to update these
forward-looking statements. We disclaim any obligation to update any such
factors or to publicly announce the result of any revisions to any of the
forward-looking statements contained herein to reflect future results, events
or developments, unless required to do so by a governmental authority or by
applicable law.



Investor Relations
Ginette Beaudet Vallières
Investor Relations Coordinator
(418) 652-8525 ext. 265

Media Relations
Paul Burroughs
Director of Communications
(418) 652-8525 ext. 406
Press spacebar to pause and continue. Press esc to stop.